FTRE

Fortrea Holdings Inc. Common Stock

Healthcare · Services-Medical Laboratories
$15.39+2.60% today
AI Take · AlgoThesis

Fortrea's RSI of 70.6 signals aggressive overbought territory, yet the stock sits below its 52-week high—suggesting recent momentum has stalled despite extended rallies. With an $1.4B market cap and no meaningful P/E ratio (indicating losses or distorted earnings), the company's valuation remains opaque relative to fundamentals. The 11.79% short interest isn't extreme but provides some downside cushion if sentiment reverses. The data paints a picture of a speculative healthcare services play riding technical strength into thinning air; the absence of profitability metrics combined with overbought readings implies elevated reversal risk without clear earnings anchor to support current levels.

Snapshot

Market cap
$1.4B
P/E
Forward P/E
16.3
EPS (TTM)
$-4.91
Dividend yield
Net margin
-16.5%
ROE
-79.1%
RSI (14)
71
Beta
3.00
Short % of float
11.8%
Days to cover
6.0
52w high
No

Peers in Services-Medical Laboratories

Build a thesis around FTRE

Type a thesis in plain English. AlgoThesis researches it with real data, cites sources, and hands back a tradeable basket.

Open in AlgoThesis →